Spelling suggestions: "subject:"72skeletal muscle,"" "subject:"loskeletal muscle,""
51 |
An investigation of the interaction between AMP-activated protein kinase subunitsCheung, Peter Ching For January 2000 (has links)
No description available.
|
52 |
Molecular analysis of dystrobrevinNawrotzki, Ralph January 1997 (has links)
No description available.
|
53 |
Next-generation sequencing methylation profiling of subjects with obesity identifies novel gene changesDay, Samantha E., Coletta, Richard L., Kim, Joon Young, Campbell, Latoya E., Benjamin, Tonya R., Roust, Lori R., De Filippis, Elena A., Dinu, Valentin, Shaibi, Gabriel Q., Mandarino, Lawrence J., Coletta, Dawn K. 18 July 2016 (has links)
Background: Obesity is a metabolic disease caused by environmental and genetic factors. However, the epigenetic mechanisms of obesity are incompletely understood. The aim of our study was to investigate the role of skeletal muscle DNA methylation in combination with transcriptomic changes in obesity. Results: Muscle biopsies were obtained basally from lean (n = 12; BMI = 23.4 +/- 0.7 kg/m(2)) and obese (n = 10; BMI = 32.9 +/- 0.7 kg/m(2)) participants in combination with euglycemic-hyperinsulinemic clamps to assess insulin sensitivity. We performed reduced representation bisulfite sequencing (RRBS) next-generation methylation and microarray analyses on DNA and RNA isolated from vastus lateralis muscle biopsies. There were 13,130 differentially methylated cytosines (DMC; uncorrected P < 0.05) that were altered in the promoter and untranslated (5' and 3'UTR) regions in the obese versus lean analysis. Microarray analysis revealed 99 probes that were significantly (corrected P < 0.05) altered. Of these, 12 genes (encompassing 22 methylation sites) demonstrated a negative relationship between gene expression and DNA methylation. Specifically, sorbin and SH3 domain containing 3 (SORBS3) which codes for the adapter protein vinexin was significantly decreased in gene expression (fold change -1.9) and had nine DMCs that were significantly increased in methylation in obesity (methylation differences ranged from 5.0 to 24.4 %). Moreover, differentially methylated region (DMR) analysis identified a region in the 5' UTR (Chr. 8: 22,423,530-22,423,569) of SORBS3 that was increased in methylation by 11.2 % in the obese group. The negative relationship observed between DNA methylation and gene expression for SORBS3 was validated by a site-specific sequencing approach, pyrosequencing, and qRT-PCR. Additionally, we performed transcription factor binding analysis and identified a number of transcription factors whose binding to the differentially methylated sites or region may contribute to obesity. Conclusions: These results demonstrate that obesity alters the epigenome through DNA methylation and highlights novel transcriptomic changes in SORBS3 in skeletal muscle.
|
54 |
Effects of Carbohydrate Availability on Fatigue and Fatigue Pre-Conditioning in Mouse FDB MuscleHesse, Erik 19 August 2019 (has links)
To prevent damaging ATP depletion during periods of intense activity‚ intrinsic mechanisms within skeletal muscle are activated and lead to myoprotection; a process known as muscle fatigue. It has been proposed that the primary mechanism of fatigue is a submaximal sarcoplasmic reticulum Ca2+ release and decreased force generation‚ however‚ what triggers this mechanism remains controversial. It is possible that glycogen may act as a trigger as studies have repeatedly shown a direct correlation between glycogen content at the beginning of activity and time to fatigue. In previous studies‚ a fatigue bout and/or period of fasting to deplete glycogen was used. However, this leaves investigators to differentiate between the effects of glycogen depletion methodology causing a metabolic stress and effects of glycogen itself. One objective of this M.Sc. project was to produce a low glycogen model without a prior metabolic stress that could forgo these limitations. It was extended to differentiate between the role of glycogen and extracellular glucose during fatigue as well as fatigue pre-conditioning (FPC)‚ a phenomenon in which fatigue resistance increases for about 2 hours after a first fatigue bout. During a single‚ first fatigue bout (one contraction every sec for 3 min) a mean decrease in glycogen from 95 to 20 μmol/g dry wt. had no effect on the decrease in tetanic [Ca2+]i‚ i.e. the [Ca2+]i during tetanic contractions‚ whereas removing glucose from the physiological solution led to a 46% greater decrease in tetanic [Ca2+]i than when glucose was present. During a subsequent fatigue bout (i.e. FPC) a greater amount of glycogen was used as glycogen content was 27% greater than prior to the first fatigue bout. When glycogen and/or glucose was limited‚ FPC was abolished. It is concluded that extracellular glucose is critical to prevent fatigue. Additionally, whereas glycogen is important for FPC‚ it appears to be much less important during a first fatigue bout initiated in absence of any prior metabolic stress.
|
55 |
Evaluation de régulateurs positifs de la croissance musculaire chez un modèle dystrophique murin / Evaluation of positive regulators of muscle growth in a murine dystrophic modelGuiraud, Simon 18 November 2011 (has links)
En 1997, le caractère culard, un phénotype hypermusclé chez le bovin, est attribué à des mutations dans le gène de la myostatine (MSTN). Depuis, il a été confirmé qu’une baisse de l’activité de la MSTN conduisait à une augmentation de la masse musculaire chez d’autres espèces, y compris chez l’Homme. L’identification de ce facteur et des conséquences de son invalidation sur le développement musculaire ouvre de nombreuses perspectives en médecine humaine comme, par exemple, chez des personnes ayant eu une fonte musculaire importante suite à une immobilisation prolongée ou en conséquence du vieillissement ou d’une maladie chronique. L’objectif majeur de ce projet de recherche a consisté à évaluer de nouvelles stratégies permettant d’augmenter la masse musculaire chez la souris. Pour ce faire, nous nous sommes intéressés à une métalloprotéine de la matrice extracellulaire (MEC), la décorine (DCN), dont l’interaction avec la MSTN a été caractérisée comme étant zinc dépendante. Suite à l’injection de ce Small Leucine Rich Proteoglycan (SLRP) chez la souris dystrophique mdx et Gamma-sarcoglycan-/-, nous avons constaté une augmentation de la masse musculaire consécutive à un phénomène d’hypertrophie associé ou non à de l’hyperplasie. Des études de dose/cinétique ont montré que l’effet positif de la décorine sur la croissance musculaire était maximal 21 jours après administration. Nous avons également découvert qu’un fragment peptidique de 41 acides aminés du domaine N-terminal de la protéine DCN murine conservait une activité anti-myostatine et induisait une hypertrophie musculaire chez la souris dystrophique. Ce domaine, site de l’interaction directe entre la MSTN et la DCN, présente un motif CX3CXCX6C, caractéristique des SLRPs de classe I, dont le cluster de cystéines et son interaction avec le zinc ont été décrits comme indispensables à l’activité anti-MSTN de la DCN. Différentes études concernant les mécanismes induits lors de la séquestration de la MSTN par la DCN dans la MEC ont également été conduites afin d’expliquer les phénomènes observés chez la souris. Enfin, nous avons étudié le potentiel de la DCN pour favoriser la greffe de cellules myogéniques et développé différentes approches de thérapie génique. / In 1997, the double-muscling phenotype, a marked hypermuscularity in cattle, was related to mutations in the myostatin (MSTN) gene. Since, it was confirmed that a decrease of the myostatin’s activity drives an increase of the muscular mass in others species, including Human. The identification of this factor and the consequences of its invalidation on the muscular development open many perspectives in human medicine, as, for example, for people whom have an important muscular loss fallow up an extended immobilization or in consequence of old age or a chronic disease. The main purpose of this research project was to evaluate some new strategies permitting the increase of the muscular mass in mice. To achieve that, we investigated in detail the decorin (DCN), a metalloprotein of the extracellular matrix (ECM), interacting with MSTN in a zinc-dependent manner. After intramuscular injection of this Small Leucine Rich Proteoglycan (SLRP) in mdx and Gamma-Sarcoglycan-/- dystrophic mice, we observed a significant increase of the muscle mass conducted by hypertrophy associated or not with hyperplasia. Dose and cinetic studies showed that the positive effect of the decorin on muscular growth was maximal 21 days after administration. Furthermore, we showed that a peptide encompassing the 31-71 sequence retains full myostatin binding capacity and intramuscular injection of this peptide induces muscle hypertrophy in dystrophic mice. This direct interaction site between MSTN and DCN contains a conserved CX3CXCX6C pattern of class I SLRPs, whose cluster of cysteins and its interaction with zinc were shown to be crucial in the anti-MSTN activity of DCN. Various studies of the mechanism resulting of the sequestration of MSTN by DCN in ECM were conducted in order to explain the phenomenom observed in mice. Al last, we have studied the potential of DCN in the cellular transplantation and developped different anti-myostatin strategies of genetic therapy.
|
56 |
Design and additive manufacture of microphysiological perfusion systems for pharmaceutical screening of tissue engineered skeletal muscleRimington, Rowan P. January 2018 (has links)
The methodologies utilised by pharmaceutical companies for the toxicity screening of developmental drugs are currently based on outdated two-dimensional (2D) plate-based assay systems. Although such methods provide high-throughput analysis, limitations surrounding the biomimicry of the culture environment reduces the accuracy of testing, making the process cost and time inefficient. To significantly enhance the current methods, a screening platform that is both flexible in its design and is amenable toward physiologically representative engineered tissue is required. Incorporating a flow environment within the system elicits a variety of advantages over standard static cultures, pertinently the ability to couple the flow path with automated analytical systems via the use of intuitive software. Musculoskeletal pathological conditions account for £4.76 billion of NHS spending as of 2011 (Department of Health), affecting one in four of the UK adult population. Skeletal muscle, a highly metabolic and regenerative tissue, is involved in a wide variety of functional, genetic, metabolic and degenerative pathological conditions such as muscular dystrophy, diabetes, osteoarthritis, motor neuron disease and pertinently muscular weakness associated with aging populations. Skeletal muscle tissue engineering is centred on the in vitro creation of in vivo-like tissue within laboratory environments and seeks to aid the development of future therapies, by reliably elucidating the molecular mechanisms that regulate such conditions. However, the translation of such models toward systems amenable to pharmaceutical companies has to date been limited. Microphysiological perfusion bioreactors for in vitro cell culture are a rapidly developing research niche, although state of the art systems are currently limited due to the biologically non-representative 2D culture environment, lack of adaptability toward different experimental requirements and confinement to offline analytical methods. Advancements in additive manufacture (AM), commonly known as three-dimensional (3D) printing has provided a method of production that enables researchers to hold complete design freedom and facilitate customisation of required parts. The low cost, rapid prototyping nature of AM further lends itself toward the development of such technology, with design iterations quickly and easily printed, tested and re-designed where appropriate. Issues do however, currently persist regarding the biological compatibility of printed polymers and functional material properties of parts created. As such, this thesis investigated the use of AM as a rapid and functional prototyping technique to design and develop microphysiological perfusion bioreactors. Here, biocompatibility of candidate polymers derived from commercially available 3D printing processes; fused deposition modelling (FDM), stereolithography (SL), selective laser sintering (LS) and PolyJet modelling (PJM) were elucidated. Following the biological evaluation of these polymers, their suitability, and the applicability of each process in function and manufacture of perfusion bioreactors were assessed alongside the research and development process of system designs. Specifically, attention was afforded to the homeostatic environment within bio-perfusion systems. Once finalised, the biological optimisation of designs; biocompatibility and rates of proliferation in response to the perfusion environment, was undertaken. Protocols were then established for the automated perfusion of skeletal muscle cells in both monolayer and tissue engineered 3D hydrogels. This research outlined significant contributions to the scientific literature in 3D printed polymer biocompatibility, in addition to creating bio-perfusion systems that are adaptable, analytical and facilitate the in situ phenotypic development of physiologically representative skeletal muscle tissue. Polymer biocompatibility elucidated in this work will help to facilitate the wide-ranging use of AM in biological settings. However, advancements in the chemical properties of liquid resins for advanced photo-curable processes remain necessitated for AM to be considered as a primary manufacturing technique in the biological sciences. Furthermore, although systems developed in this work have provided a base technology from which to develop and build upon, significant challenges remain in the integration of tissue engineered perfusion devices within pharmaceutical settings. Although it is plausible that the technology created in its current guise would facilitate the automated generation of skeletal muscle tissue, systems require further development to aid their usability and scale. Furthermore, work is also required to optimise the biological environment prior to mass manufacture. As such, to truly influence the pharmaceutical industry, which has invested so heavily in more traditional screening technology, a system that is all-encompassing in biology, technology and automated analytics is required.
|
57 |
Effects of Curcumin and Ursolic Acid on the Mitochondrial Coupling Efficiency and Hydrogen Peroxide Emission of Intact Skeletal MyoblastsTueller, Daniel J. 01 July 2017 (has links)
Curcumin is a natural compound that improves blood glucose management. While some evidence from isolated mitochondria indicates that curcumin uncouples electron transport from oxidative phosphorylation, the effects of curcumin on mitochondrial respiration and hydrogen peroxide emission in intact skeletal muscle cells are not known. By assessing rates of oxygen consumption, we demonstrated for the first time that curcumin (40 µM) reduced the mitochondrial coupling efficiency (percentage of oxygen consumption that supports ATP synthesis) of intact skeletal muscle cells. A 30-minute incubation with curcumin decreased mitochondrial coupling efficiency by 17.0 ± 0.4% relative to vehicle (p < 0.008). Curcumin also decreased the rate of hydrogen peroxide emission by 43 ± 13% compared to vehicle (p < 0.05). Analysis of cell respiration in the presence of curcumin revealed a 40 ± 4% increase in the rate of oxygen consumption upon curcumin administration (p < 0.05 compared to vehicle). In additional experiments, no difference in mitochondrial coupling efficiency was observed between vehicle- and curcumin-pretreated cells after permeabilization of cell membranes (p > 0.7). The possibility of synergistic effects between curcumin and ursolic acid, another natural compound that improves blood glucose management, was also examined. Interestingly, ursolic acid (0.12 µM) increased mitochondrial coupling efficiency by 4.1 ± 1.1% relative to vehicle (p < 0.008) and attenuated the effect of curcumin when the two compounds were used in combination (decreased mitochondrial coupling efficiency by 8.0 ± 0.9% compared to vehicle, p < 0.008). These results provide evidence for lower mitochondrial coupling efficiency and hydrogen peroxide emission as possible contributors to the increased glucose uptake and insulin sensitivity of subjects after treatment with curcumin but not ursolic acid. Unless cells are assessed in the intact condition, changes to mitochondrial coupling efficiency after curcumin treatment may go unnoticed.
|
58 |
The Effect of Exercise-induced Myokines on Placental Health and FunctionDubé, Chantal January 2017 (has links)
Background: Exercise in pregnancy is associated with optimized fetal growth; however, the implicated mechanisms remain unknown. We hypothesize that exercise-induced myokines may be acting on the placenta to optimize fetal growth across gestation.
Methodology: 1) Circulating profiles of 11 myokines were analyzed in 2nd trimester plasma of women characterized as active (N=14) or non-active (N=16) during pregnancy. 2) First trimester human placental explants (N=5) were treated with SPARC in a dose-dependent manner (0-150ng/ml). Metrics of placental health/function, including GLUT-4 expression/regulation, were assessed.
Results: 1) Active women demonstrated an elevation in circulating SPARC compared to non-active women (86±19pg/ml vs. 52±18pg/ml, p=0.0001). 2) Explants treated with SPARC at 100ng/ml demonstrated improved invasion, with improved maximum outgrowth distance (N=3; p=0.0219).
Conclusion: SPARC is a myokine that is elevated in the circulation of active pregnant women and is associated with improved placental invasion, suggesting a possible role of SPARC in placentation.
|
59 |
Investigating the potential relationship between skeletal muscle atrophy and obesityElmore, Christopher John 01 July 2012 (has links)
Skeletal muscle atrophy is the most common clinical disorder of skeletal muscle and typically occurs as a secondary consequence of fasting, disuse, acute and chronic illness, and aging. It can lead to prolonged recovery and loss of independent living. Of similar clinical significance, one third of Americans are obese and at risk for metabolic syndrome. Interestingly recent studies have demonstrated that both metabolic syndrome and obesity diminish skeletal muscle strength, power, and endurance. However, there are no effective pharmacological treatments for these debilitating effects on skeletal muscle. This is largely due to the fact that the molecular mechanisms underlying its pathogenesis remain uncharacterized. We have recently identified ursolic acid (UA) as a small molecule inhibitor of muscle atrophy. In the absence of atrophy-inducing stress, UA-supplemented chow elicited muscle hypertrophy with little adiposity in mice. To further evaluate these data, mice were subjected to a high fat diet (HFD) with or without UA supplementation, or a standard chow (SC) control. Our data indicates that UA-supplemented HFD mitigates muscle atrophy and adiposity, while HFD significantly reduces muscle mass compared to SC. Furthermore, mice fed a HFD exhibited increased adiposity and reduced muscle mass, strength, and fiber diameter when compared to SC controls. Molecular analysis revealed diminished protein content and increased triglycerides. Gene expression analysis revealed a reduction in Pgc1α, a critical gene that regulates oxidative metabolism and mitochondrial biogenesis. Additionally, we found decreased expression of hormonal receptors AR, involved in signaling of testosterone, and Thrα, involved in signaling of thyroid hormones. Taken together, these data suggest that alterations in gene expression resulting from diet-induced obesity are an atrophy-inducing stress that may function by disrupting metabolic and hormonal signaling.
|
60 |
Chracterisation of Mighty during Skeletal Muscle RegenerationDyer, Kelly Anne January 2006 (has links)
Satellite cells are a distinct lineage of myogenic precursors that are responsible for the growth of muscle during post-natal life and for its repair after damage. During muscle growth and regeneration satellite cells are activated in response to growth signals from the environment, which induces the expression of one or both of the two MRFs, Myf-5 or MyoD. Activated satellite cells migrate to the site of injury and proliferate before these transcription factors go on to activate transcription of myogenic genes. The myoblasts can then adopt one of two fates. Some myoblasts initiate terminal differentiation and are able to either fuse into existing myofibres to repair them, or fuse with other myoblasts to form new fibres. Other myoblasts do not differentiate but instead return to quiescence and adopt a satellite cell position on repaired or newly formed fibres. Mighty, a downstream target of myostatin that was discovered by the Functional Muscle Genomics Laboratory has recently been shown to induce cell hypertrophy in cell culture through enhanced differentiation and fusion of myoblasts. Myostatin-null mice have hypertrophic muscles and an improved muscle regeneration phenotype. These mice have also been shown to have higher basal levels of Mighty in skeletal muscle than wild-type mice. In this thesis the expression profile of Mighty during skeletal muscle regeneration was characterised in relation to MyoD. During regeneration Mighty gene expression was induced at day five post-injury in both wild-type and myostatin-null mice. In the myostatin-null mice Mighty gene expression remained elevated at day seven post injury in contrast to the levels in the wild-type, which had decreased at this time point. By day-14 and day-28 post-injury Mighty levels were decreased. The up-regulation of Mighty occurs at the time of peak myotube formation in regenerating skeletal muscle, consistent with a role for Mighty in enhancing differentiation and fusion of myoblasts. The extended up-regulation of Mighty in the myostatin-null muscle may be responsible for the enhanced regeneration phenotype of these mice. Analysis of the myotube and reserve cell populations, which are an in vitro model of satellite cells, from both C2C12 cells and Mighty over-expressing clones (Clone 7 and Clone 11) showed that Mighty expression down-regulates two satellite cell markers, CD34 and Sca-1. Both these molecules have been recently shown to be involved in myoblast fusion and reserve cell specification, although their exact role in these processes is not yet known. Expression of Sca-1 is associated with a slowly proliferating non-dividing state while CD34 is associated with the population of reserve cells that do not fuse when notch signalling is inhibited. The results of this thesis indicate that Mighty over-expression may cause the enhanced fusion phenotype by regulating these two molecules. In conclusion the data in this thesis supports a role for Mighty in the myotube formation phase of regeneration and may be able to enhance regeneration by recruiting more myoblasts to terminal differentiation by altering CD34 and Sca-1 expression.
|
Page generated in 0.0557 seconds